Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: A phase II trial

Gynecologic Oncology

Volumn 105, Issue 2, 2007, Pages 358-364

  Kushner, David M ^a   Connor, Joseph P ^a   Sanchez, Federico ^b   Volk, Michael ^c   Schink, Julian C ^d   Bailey, Howard H ^a   Harris, Linda S ^a   Stewart, Sarah L ^a   Fine, Jason ^a   Hartenbach, Ellen M ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b Regional Cancer Center at Oconomowoc/Waukesha Memorial Hospitals   (United States)

^c Green Bay Oncology ^*  (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

CA 125; Carboplatin; Docetaxel; Ovarian cancer; Phase II; Primary peritoneal cancer; Quality of life; Weekly regimen

Indexed keywords

CARBOPLATIN; DIPHENHYDRAMINE; DOCETAXEL; PLATINUM; TAXANE DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; QUALITY OF LIFE; TAXOIDS;

EID: 34247209201     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.12.018     Document Type: Article

References (50)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics, 2006. CA Cancer J. Clin. 56 2 (2006) 106-130
2. Swenerton K., Jeffrey J., Stuart G., Roy M., Krepart G., Carmichael J., et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 10 5 (1992) 718-726
3. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334 1 (1996) 1-6
4. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21 17 (2003) 3194-3200
5. Markman M., and Bookman M.A. Second-line treatment of ovarian cancer. Oncologist. 5 1 (2000) 26-35
6. Armstrong D.K. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 7 Suppl. 5 (2002) 20-28
7. Thigpen T., Vance R.B., McGuire W.P., Hoskins W.J., and Brady M. The role of paclitaxel in the management of coelomic epithelial carcinoma of the ovary: a review with emphasis on the Gynecologic Oncology Group experience. Semin. Oncol. 22 6 Suppl. 14 (1995) 23-31
8. Markman M., Rothman R., Hakes T., Reichman B., Hoskins W., Rubin S., et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. 9 3 (1991) 389-393
9. Rose P.G., Fusco N., Fluellen L., and Rodriguez M. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J. Clin. Oncol. 16 4 (1998) 1494-1497
10. Ransom D.T., Patel S.R., Keeney G.L., Malkasian G.D., and Edmonson J.H. Papillary serous carcinoma of the peritoneum. A review of 33 cases treated with platin-based chemotherapy. Cancer 66 6 (1990) 1091-1094
11. Menzin A.W., Aikins Jr. J.K., Wheeler J.E., and Rubin S.C. Surgically documented responses to paclitaxel and cisplatin in patients with primary peritoneal carcinoma. Gynecol. Oncol. 62 1 (1996) 55-58
12. Parmar M.K., Ledermann J.A., Colombo N., du Bois A., Delaloye J.F., Kristensen G.B., et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 361 9375 (2003) 2099-2106
13. Rose P.G., and Smrekar M. Improvement of paclitaxel-induced neuropathy by substitution of docetaxel for paclitaxel. Gynecol. Oncol. 91 2 (2003) 423-425
14. Markman M., Kennedy A., Webster K., Peterson G., Kulp B., and Belinson J. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J. Clin. Oncol. 19 7 (2001) 1901-1905
15. Vasey P.A., Atkinson R., Coleman R., Crawford M., Cruickshank M., Eggleton P., et al. Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. Br. J. Cancer 84 2 (2001) 170-178
16. Pfisterer J., du Bois A., Wagner U., Quaas J., Blohmer J.U., Wallwiener D., et al. Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynakologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group. Gynecol. Oncol. 92 3 (2004) 949-956
17. Vasey P.A., Jayson G.C., Gordon A., Gabra H., Coleman R., Atkinson R., et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J. Natl. Cancer Inst. 96 22 (2004) 1682-1691
18. Markman M., Blessing J., Rubin S.C., Connor J., Hanjani P., and Waggoner S. Phase II trial of weekly paclitaxel (80 mg/m(2)) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol. Oncol. (2005)
19. Markman M., and Fowler J. Activity of weekly paclitaxel in patients with advanced endometrial cancer previously treated with both a platinum agent and paclitaxel. Gynecol. Oncol. 92 1 (2004) 180-182
20. Markman M., Blessing J., Rubin S.C., Connor J., Hanjani P., and Waggoner S. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol. Oncol. 101 3 (2006) 436-440
21. Rosenberg P., Andersson H., Boman K., Ridderheim M., Sorbe B., Puistola U., et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol. 41 5 (2002) 418-424
22. Markman M. Weekly paclitaxel in the management of ovarian cancer. Semin. Oncol. 27 3 Suppl. 7 (2000) 37-40
23. Fennelly D., Aghajanian C., Shapiro F., O'Flaherty C., McKenzie M., O'Connor C., et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J. Clin. Oncol. 15 1 (1997) 187-192
24. Baker S.D., Zhao M., Lee C.K., Verweij J., Zabelina Y., Brahmer J.R., et al. Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin. Cancer Res. 10 6 (2004) 1976-1983
25. Burstein H.J., Manola J., Younger J., Parker L.M., Bunnell C.A., Scheib R., et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J. Clin. Oncol. 18 6 (2000) 1212-1219
26. Hainsworth J.D., Burris III H.A., Litchy S., Morrissey L.H., Barton J.H., Bradof J.E., et al. Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial. Cancer. 89 2 (2000) 328-333
27. Berkenblit A., Seiden M.V., Matulonis U.A., Penson R.T., Krasner C.N., Roche M., et al. A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecol. Oncol. 95 3 (2004) 624-631
28. Sehouli J., Stengel D., Elling D., Ortmann O., Blohmer J., Riess H., et al. First-line chemotherapy with weekly paclitaxel and carboplatin for advanced ovarian cancer: a phase I study. Gynecol. Oncol. 85 2 (2002) 321-326
29. Watanabe Y., Nakai H., Ueda H., and Hoshiai H. Evaluation of weekly low-dose paclitaxel and carboplatin treatment for patients with platinum-sensitive relapsed ovarian cancer. Gynecol. Oncol. 96 2 (2005) 323-329
30. Kikuchi A., Sakamoto H., and Yamamoto T. Weekly carboplatin and paclitaxel is safe, active, and well tolerated in recurrent ovarian cancer cases of Japanese women previously treated with cisplatin-containing multidrug chemotherapy. Int. J. Gynecol. Cancer 15 1 (2005) 45-49
31. Rein D.T., Kurbacher C.M., Breidenbach M., Schondorf T., Schmidt T., Konig E., et al. Weekly carboplatin and docetaxel for locally advanced primary and recurrent cervical cancer: a phase I study. Gynecol. Oncol. 87 1 (2002) 98-103
32. Rustin G.J., Nelstrop A.E., McClean P., Brady M.F., McGuire W.P., Hoskins W.J., et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J. Clin. Oncol. 14 5 (1996) 1545-1551
33. Rustin G.J., Nelstrop A.E., Bentzen S.M., Bond S.J., and McClean P. Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials. J. Clin. Oncol. 18 8 (2000) 1733-1739
34. Jelliffe R.W. Letter: creatinine clearance: bedside estimate. Ann. Intern. Med. 79 4 (1973) 604-605
35. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92 3 (2000) 205-216
36. Cella D.F., Tulsky D.S., Gray G., Sarafian B., Linn E., Bonomi A., et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J. Clin. Oncol. 11 3 (1993) 570-579
37. Basen-Engquist K., Bodurka-Bevers D., Fitzgerald M.A., Webster K., Cella D., Hu S., et al. Reliability and validity of the functional assessment of cancer therapy-ovarian. J. Clin. Oncol. 19 6 (2001) 1809-1817
38. Calhoun E.A., Welshman E.E., Chang C.H., Lurain J.R., Fishman D.A., Hunt T.L., et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int. J. Gynecol. Cancer 13 6 (2003) 741-748
39. Wenzel L., Huang H.Q., Monk B.J., Rose P.G., and Cella D. Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 23 24 (2005) 5605-5612
40. Nicoletto M.O., Falci C., Pianalto D., Artioli G., Azzoni P., De Masi G., et al. Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer. Gynecol. Oncol. 100 2 (2006) 318-323
41. Rose P.G., Smrekar M., Haba P., Visser C., and Beeler J.F. A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma. Gynecol. Oncol. 99 3 (2005) 714-719
42. Rustin G.J., Marples M., Nelstrop A.E., Mahmoudi M., and Meyer T. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J. Clin. Oncol. 19 2 (2001) 4054-4057
43. Rustin G.J., Timmers P., Nelstrop A., Shreeves G., Bentzen S.M., Baron B., et al. Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. J. Clin. Oncol. 24 1 (2006) 45-51
44. Gronlund B., Hogdall C., Hilden J., Engelholm S.A., Hogdall E.V., and Hansen H.H. Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?. J. Clin. Oncol. 22 20 (2004) 4051-4058
45. Markman M., Kennedy A., Webster K., Elson P., Peterson G., Kulp B., et al. Clinical features of hypersensitivity reactions to carboplatin. J. Clin. Oncol. 17 4 (1999) 1141
46. Navo M., Kunthur A., Badell M.L., Coffer Jr. L.W., Markman M., and Brown J. Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients. Gynecol. Oncol. 103 2 (2006) 608-613
47. Markman M., Zanotti K., Peterson G., Kulp B., Webster K., and Belinson J. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J. Clin. Oncol. 21 24 (2003) 4611-4614
48. Zanotti K.M., Rybicki L.A., Kennedy A.W., Belinson J.L., Webster K.D., Kulp B., et al. Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J. Clin. Oncol. 19 12 (2001) 3126-3129
49. Lee C.W., Matulonis U.A., Castells M.C., et al. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol. Oncol. 95 2 (2004) 370-376
50. Rose P.G., Fusco N., Smrekar M., Mossbruger K., Rodriguez M., et al. Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity. Gynecol. Oncol. 89 3 (2003) 429-433